A Phase 3, Multicenter, Double-Blind, Placebo-Controlled, Single-Treatment Efficacy and Safety Study of MYOBLOC (Part A) Followed by Open-Label, Multiple-Treatment With MYOBLOC (Part B) in the Treatment of Troublesome Sialorrhea in Adult Subjects
Latest Information Update: 14 Jul 2021
At a glance
- Drugs Botulinum toxin B (Primary)
- Indications Sialorrhoea
- Focus Registrational; Therapeutic Use
- Acronyms MYSTICOL
- Sponsors US WorldMeds
- 01 May 2020 Results, assessing the onset of action for rimabotulinumtoxinB injections in the salivary glands for the treatment of sialorrhea. presented at the 72nd Annual Meeting of the American Academy of Neurology
- 13 Jan 2020 Results published in the JAMA Neurology
- 28 Apr 2017 Results presented at the 69th Annual Meeting of the American Academy of Neurology